Pharmacogenetics of SGLT2 Inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker

Simeon I. Taylor[1]*. Hua-Ren Cherng[2], Zhinous Shahidzadeh Yazdi[1], May E. Montasser[1], Hilary B. Whitlatch[1], Braxton D. Mitchell[1], Alan R. Shuldiner[1], Elizabeth A. Streeten[1], and Amber L. Beitelshees[1]

[1] Department of Medicine
Division of Endocrinology, Diabetes, and Nutrition
University of Maryland School of Medicine
Baltimore, MD 20201
USA

[2] Department of Radiation Oncology
University of Maryland School of Medicine
Baltimore, MD 20201
USA

* Correspondence: sitaylormd@aol.com

Key words: canagliflozin, diabetes, kidney, pharmacogenomics, precision medicine, sex as a biological variable, sodium-glucose cotransporter-2, type 2 diabetes, uric acid

Abstract

Aim: SGLT2 inhibitors provide multiple benefits to patients with type 2 diabetes – including improved glycemic control and decreased risks of cardiorenal disease. Because drug responses vary among individuals, we initiated investigations to identify genetic variants associated with the magnitude of drug responses.

Methods: Canagliflozin (300 mg) was administered to 30 healthy volunteers. Several endpoints were measured to assess clinically relevant responses – including drug-induced increases in urinary excretion of glucose, sodium, and uric acid.

Results: This pilot study confirmed that canagliflozin (300 mg) triggered acute changes in mean levels of several biomarkers: fasting plasma glucose (-4.1 mg/dL; $p=6x10^{-5}$), serum creatinine (+0.05 mg/dL; $p=8x10^{-4}$), and serum uric acid (-0.90 mg/dL; $p=5x10^{-10}$). The effects of sex on glucosuria depended upon how data were normalized. Whereas males' responses were ~60% greater when data were normalized to body surface area, males and females exhibited similar responses when glucosuria was expressed as grams of urinary glucose per gram-creatinine. The magnitude of glucosuria was not significantly correlated with fasting plasma glucose, estimated GFR, or age in these healthy non-diabetic individuals with estimated GFR>60 mL/min/1.73m^2.

Conclusions: Normalizing data relative to creatinine excretion will facilitate including data from males and females in a single analysis. Furthermore, because our ongoing pharmacogenomic study (NCT02891954) is conducted in healthy individuals, this will facilitate detection of genetic associations with limited confounding by other factors such as age and renal function.

Registration: NCT02462421 (clinicaltrials.gov)

Funding: Research grants from the National Institute of Diabetes and Digestive and Kidney Diseases: R21DK105401, R01DK108942, T32DK098107, and P30DK072488.

64 # 1 | INTRODUCTION

65 Although head-to-head comparative effectiveness studies demonstrate that diabetes drugs are
66 not strongly differentiated with respect to mean HbA1c-lowering [1], there is wide variation in
67 individual responses to the same therapy. A recent head-to-head study reported HbA1c-
68 lowering efficacies (mean ± SEM) of 0.89% ± 0.24% for canagliflozin and 1.44% ± 0.39% for
69 liraglutide [2]. This corresponds to standard deviations of ~0.9% and ~1.5%, respectively. While
70 some patients experienced little if any decrease in HbA1c, others experienced >2.5% HbA1c-
71 lowering. This inter-individual variation results from a combination of genetic and environmental
72 factors. Pharmacogenetics has potential to provide insights enabling physicians to prescribe
73 therapies for individual patients based on predictors of individual responses and risks of
74 adverse effects [1].

75 Pharmacogenomics has identified genetic variants contributing to inter-individual variation in
76 responses to diabetes drugs [3-7]. Some genetic variants alter pharmacokinetics by altering
77 function of drug transporters or drug metabolizing enzymes [3,8]. Other genetic variants alter
78 functions of proteins that mediate drug responses, thereby altering pharmacodynamics [4,6,9]. This
79 pilot study represents one step toward identifying genetic variants contributing to inter-individual
80 variation in responses to SGLT2 inhibitors – an increasingly important class of diabetes drugs
81 [10,11]. Glucuronidation is the principal pathway whereby SGLT2 inhibitors are metabolized. Loss-
82 of-function variants in glucuronidation enzymes alter pharmacokinetics of SGLT2 inhibitors by
83 increasing drug exposure [8], but these variants are unlikely to cause major alterations in drug
84 responses in routine clinical use because SGLT2 inhibitors are usually administered at
85 maximally effective doses. Increasing drug exposure may not alter responses to drugs that are
86 administered at maximally effective doses.

87 Several approaches have been applied in pharmacogenomic research – including acute studies
88 in healthy volunteers assessing pharmacodynamic endpoints [3,12] or chronic studies in disease

89 patients assessing clinical endpoints such as HbA1c or cardiovascular outcomes [9,12]. Short-term
90 studies in healthy volunteers offer methodological advantages – including minimization of
91 confounding factors due to co-existing diseases and effects of changing co-medications during
92 the study. This pilot study provided an opportunity to validate pharmacodynamic endpoints for
93 our ongoing GWAS of pharmacodynamic responses to canagliflozin (NCT02891954). Our
94 approach was inspired by high priority NIH initiatives: (a) scientific rigor and reproducibility [13];
95 (b) investigation of sex as a biological variable [14]; and (c) precision medicine [15].

96 Research participants collected two separate 24-hour urine collections. We confirmed the
97 reproducibility of urine collections as indicated by absence of a statistically significant difference
98 in creatinine content between the two separate urine collections – a critical prerequisite for our
99 twin objectives of minimizing the impact of random variation and maximizing the impact of
100 genetic variation. This pilot study also investigated the impact of participants' self-designated
101 sex on pharmacodynamic responses. Mean canagliflozin-induced glucosuria was substantially
102 greater in males than females when expressed as grams of glucose per 1.73 m^2 of body
103 surface area or per kg of body weight. In contrast, mean magnitudes of canagliflozin-induced
104 glucosuria were similar in males and females when expressed as grams of glucose per gram of
105 creatinine. Accordingly, our ongoing pharmacogenomic study will normalize drug-induced
106 glucosuria data relative to urinary creatinine excretion so that the magnitude of canagliflozin-
107 induced glucosuria would be relatively independent of sex ("sex-agnostic").

108 2 | METHODS

109 2. 1 | Study population

110 The Old Order Amish population of Lancaster County, PA immigrated to the Colonies from
111 Central Europe in the early 1700's. There are currently ~40,000 Old Order Amish individuals in
112 Lancaster County, PA – nearly all of whom trace their ancestry back ~15 generations to ~750

113 founders [16-18]. Investigators at the University of Maryland Baltimore have investigated genetic
114 determinants of cardiometabolic health in this population since 1993. These studies generated a
115 genotype database used to compile a list of individuals to be invited to participate in this clinical
116 trial. Individuals with any of four homozygous genotypes were eligible to participate: (a)
117 nonsense mutation in *SLC5A4* (rs62239058); (b) nonsense mutation in *SLC5A9* (rs850763); (c)
118 missense variant in *SLC2A*9 (rs1689079); and (d) "wild type" major alleles of *SLC5A4*, *SLC5A9*,
119 and *SLC2A9*.

120 2.2 | Conduct of clinical trial (NCT02462421).

121 This clinical trial was reviewed and approved by the University of Maryland Baltimore's
122 Institutional Review Board. A research nurse accompanied by a member of the Amish
123 community made home visits to invite selected individuals to participate in the study. Potential
124 participants were invited to provide informed consent after nurses explained the study in detail.
125 Additional methodological details are summarized in the Supplementary Appendix.

126 2.3 | Statistical analyses

127 Student's t-tests as implemented in Microsoft Excel and GraphPad Prism software were used to
128 assess treatment effects (paired t-test) and differences between groups (unpaired t-tests).
129 Nominal p-values are presented without correcting for multiple comparisons. A nominal p-value
130 of <0.05 was taken as the threshold for statistical significance.

131

3 | RESULTS

3. 1 | Disposition and baseline characteristics of participants

This clinical trial assessed pharmacodynamic responses of thirty healthy Old Order Amish participants to a single dose of canagliflozin (300 mg). Disposition of the participants is summarized in Fig. S1. The study population (17 females/13 males) had a mean age of 57.8 ± 2.5 years and a mean BMI of 28.0 ± 0.9 kg/m^2 (Table S1). Baseline laboratory data are summarized in Table S1.

3.2 | Responses to canagliflozin: ↓ fasting plasma glucose, ↓ serum uric acid, and ↑ serum creatinine

Canagliflozin inhibits SGLT2, thereby decreasing proximal tubular reabsorption of glucose and sodium [10]. Drug-induced glucosuria triggered a ~4.5% decrease in mean fasting plasma glucose levels (p=0.00006; Fig. 1A). The decrease in proximal tubular sodium reabsorption induced natriuresis (Table 1, Fig. S2), which triggered a modest volume contraction as reflected by an ~8% increase in serum creatinine (p=0.0008; Fig. 1B). Canagliflozin also increased urinary excretion of uric acid, leading to a ~21% decrease in mean serum uric acid levels ($p=5 \times 10^{-10}$; Fig. 1C) [10,19-21]. Thus, administration of a single dose of canagliflozin exerted the expected pharmacodynamic effects on circulating biomarkers in healthy volunteers – thereby serving as positive controls for our clinical trials (NCT02462421 and NCT02891954).

Our primary efficacy endpoint is based on measurements of biomarkers in 24-hour urine collections. We, therefore, investigated the reproducibility of 24-hour urine collections. On average, participants excreted 1286 ± 81 mg of creatinine during the 24 hours before canagliflozin as compared to 1252 ± 74 mg of creatinine during the 24 hours after canagliflozin administration (Fig. S3A). The quantities of 24-hour urinary creatinine before and after canagliflozin administration were highly correlated with one another (r=0.95; $p=10^{-15}$). When we

156 compared creatinine contents of the two specimens collected by each individual participant,
157 differences were <5% for ~75% of paired urine collections (Fig. S3B). These data demonstrate
158 that most participants successfully obtained complete collections of urine produced during a 24-
159 hour time period.

160 ## 3. 3 | A sex-agnostic approach to normalizing urinary biomarker data.

161 Urinary excretion of glucose provides a quantitative biomarker for efficacy of canagliflozin [22-27].
162 Furthermore, enhanced urinary glucose excretion plays a critical role in mediating two important
163 benefits provided by SGLT2 inhibitors: improved glycemic control in diabetic patients and weight
164 loss in overweight/obese patients [10]. To enable pharmacogenomic investigation, it is critical to
165 optimize the approach to normalize data in order to compare glucosuric responses among
166 participants. We considered two standard approaches: (a) normalizing urinary glucose excretion
167 relative to body size (i.e., body weight or body surface area); or (b) normalizing glucosuria
168 relative to 24-hour urinary creatinine excretion. Body weight was tightly correlated with body
169 surface area (r=0.99) in both males and females (Fig. S4A), suggesting that these two
170 parameters provide comparable indices for body size. Although 24-hour urinary creatinine was
171 correlated with body surface area (r=0.68 for males and r=0.65 for females), males on average
172 excreted ~60% more creatinine than females (Fig. S4B) when compared at the same body
173 surface area. Creatinine is produced by a non-enzymatic chemical reaction – i.e., the
174 conversion of phosphocreatine to creatinine [28]. Because phosphocreatine is located primarily in
175 lean tissues (e.g., muscle), the rate of creatinine production implicitly reflects lean tissue mass.
176 When glucosuria is expressed relative to urinary excretion of creatinine, this implicitly indexes
177 glucosuria relative to lean body mass.

178 Glucosuria was correlated with urinary creatinine excretion in both males (r=0.65; Fig. 2A) and
179 females (r=0.86; Figs. 2C). Glucosuria was also correlated with body surface area (Figs. 2B and
180 2D) or body weight (Fig. S5) – albeit with smaller correlation coefficients (0.29-0.33 in males

181 and 0.54-0.55 in females). The closer correlations with urinary creatinine excretion favors the
182 approach of normalizing glucosuria relative to urinary creatinine excretion. Furthermore, this
183 approach yielded similar mean values for glucosuria in both sexes: 35.4 ± 2.0 in males versus
184 39.4 ± 1.4 g-glucose per g-creatinine in females (p=0.12; Fig. 3B). In contrast, mean values for
185 glucosuria were 37-39% larger in males than females when expressed as a function of body
186 surface area (Fig. 3A) or body weight (Fig. 3C). Thus, because mean values of glucosuria are
187 similar in both sexes when expressed on a per g-creatinine basis, this will greatly facilitate
188 including data from both sexes in the same analysis.

189 ## 3.4 | Inter-individual variation in canagliflozin-induced glucosuria.

190 We observed substantial inter-individual variation in the magnitude of canagliflozin-induced
191 increases in urinary glucose excretion. The magnitude of glucosuria varied over an
192 approximately twofold range: from ~25 to ~50 g-glucose/g-creatinine (Fig. S6). Two critical
193 factors contribute to determining the quantity of glucose filtered at the glomerulus (the "filtered
194 glucose load"): (a) plasma glucose levels and (b) glomerular filtration rates. Thus, we
195 investigated correlations of glucosuria with fasting plasma glucose levels (FPG), creatinine
196 clearance rates, and age (Fig. S7). This clinical trial focused on healthy volunteers – excluding
197 patients with HbA1c $\geq$ 6.5% or eGFR < 60 mL/min/1.73 m^2. In this population, we did not
198 observe statistically significant correlations of 24-hour urinary excretion of glucose with fasting
199 plasma glucose, measured creatinine clearance rates, or age (Fig. S7). In addition to being
200 statistically insignificant, the correlation coefficients were quite small; variances in fasting
201 plasma glucose, creatinine clearance, and age accounted for only ~1.4%, 0.5%, and 4.8% of
202 the total variance in canagliflozin-induced glucosuria, respectively. Measured creatinine
203 clearance was closely correlated with eGFR in both males and females (Fig. S8). However, we
204 focused on the measured creatinine clearance because it is likely to be a more valid index of
205 each individual's glomerular filtration rate.

206 3.5 | Canagliflozin-induced natriuresis

207 Because SGLT2 functions as a co-transporter for glucose plus Na^+, canagliflozin inhibits
208 proximal tubular reabsorption of both glucose and Na^+ [10]. Drug-induced natriuresis was
209 calculated by subtracting 24-hour urinary Na^+ excretion observed at baseline from 24-hour
210 urinary Na^+ excretion observed in the 24 hours after administration of canagliflozin.
211 Canagliflozin increased mean urinary Na^+ excretion by ~25% in the total population (N=30;
212 p=0.007) (Table 1). Research participants were free to eat *ad libitum* and to engage in their
213 usual daily activities. As no effort was made to control sodium intake, there may have been
214 substantial day-to-day variation in the sodium content of participants' diets and/or the quantity of
215 sodium lost through sweating. Such day-to-day variation represent probable sources of
216 unmeasured confounders with respect to estimates of drug-induced natriuresis. Notwithstanding
217 these caveats, estimates of drug-induced natriuresis appeared to be larger for females than
218 males – regardless of whether the magnitude of 24-hour Na^+ urinary excretion was normalized
219 relative to urinary creatinine excretion, body surface area, or body weight (Table 2).

220 3.6 | Canagliflozin-induced uricosuria

221 SGLT2 inhibitors enhance urinary excretion of uric acid and decrease serum levels of uric acid
222 [10,19-21]. Consistent with these previous publications, we observed that canagliflozin induced a 2-
223 to 10-fold increase in fractional excretion of uric acid. The magnitude of the increase in
224 fractional excretion of uric acid was correlated with the magnitude of the decrease in serum uric
225 acid levels (r=0.48; p=0.006) (Fig. 4A). Although mechanisms mediating SGLT2 inhibitor-
226 induced uricosuria have not been established, the effect may be an indirect consequence of the
227 increase in glucose concentrations in the renal tubular fluid [19]. Accordingly, we investigated
228 whether the increase in fractional excretion of uric acid was correlated with canagliflozin-
229 induced glucosuria. However, we did not detect statistically significant correlation between the

230 drug-induced increase in fractional excretion of uric acid and canagliflozin-induced glucosuria or
231 natriuresis (Fig. 4BC).

232 3.7 | Pilot pharmacogenomic investigation of genetic variants in three candidate genes
233 (SLC2A9, SLC5A4, and SLC5A9).

234 This pilot study was originally designed to investigate possible association of three candidate
235 genetic variants with pharmacodynamic responses to an SGLT2 inhibitor: nonsense variants in
236 *SLC5A4* (rs62239058; p.E139X) and *SLC5A9* (rs850763; p.E593X) and a missense variant in
237 *SLC2A9* (rs1689079; p.V253I). *SLC5A4* and *SLC5A9* encode two homologs of SGLT2 (SGLT3
238 and SGLT4, respectively) [29,30]. *SLC2A9* encodes GLUT9, a transporter reported to exchange
239 glucose for uric acid [31].

240 Because the clinical trial was terminated early when it became apparent that the clinical trial
241 would not meet its recruitment targets within the available time and budget, the study was
242 underpowered to detect association of genetic variants with drug responses. In any case, none
243 of the three genetic variants was associated with a statistically significant difference when
244 compared to the control group. (Table S2). We cannot, however, exclude the possibility that
245 these variants might exhibit significant associations in a substantially larger study with greater
246 statistical power.

247

248 # DISCUSSION

249 Following NIH's initiative to improve scientific rigor and reproducibility [13], we leveraged this pilot
250 study to validate the experimental protocol supporting our ongoing genome-wide association
251 study (GWAS) to identify genetic variants associated with pharmacodynamic responses to
252 SGLT2 inhibitors (NCT02891954). Based on quantitative comparisons of creatinine content in
253 independent 24-hour urine collections, we confirmed that research participants successfully
254 provided highly reproducible 24-hour urine collections. We did, nevertheless, observe a
255 statistically insignificant trend toward a decreased mean creatinine content (-2.6%) in the
256 second 24-hour urine collection (Fig. S3). Although not statistically significant, we suspect that
257 this small difference may be real and reproducible. Canagliflozin-induced natriuresis leads to a
258 modest volume contraction as reflected in the 6.4% increase in serum creatinine levels (Fig.
259 1B). The modestly decreased creatinine excretion during the second urine collection is
260 consistent with the expected transient decrease in urinary creatinine excretion characterizing
261 the transition between two steady-states (before and after administration of canagliflozin). Thus,
262 even the small, statistically insignificant difference between the two 24-hour urine collections
263 probably reflects the known pharmacological effects of canagliflozin rather than experimental
264 variation.

265 Furthermore, we confirmed that canagliflozin elicited the expected pharmacodynamic responses
266 and obtained information on the magnitude of inter-individual variation, which has informed
267 power calculations for our ongoing GWAS. As expected, a single dose of canagliflozin triggered
268 several statistically significant responses: fasting plasma glucose, serum uric acid, serum
269 creatinine as well as urinary excretion of sodium, glucose, and uric acid (Figs. 1-4; Table 1).
270 These data are reassuring with respect to the feasibility of our ongoing GWAS for
271 pharmacodynamic responses to canagliflozin.

272 The NIH established an expectation for NIH-supported research to include investigations of sex
273 as a biological variable in 2016 [14,32-34]. While there has been debate about the optimal approach
274 to implement this requirement, there is general agreement that sex-related variables may
275 emerge as relevant within the context of a specific research program [35]. Although some traits
276 (e.g., karyotype sex) may be dichotomous for most individuals, there are many biological traits
277 (e.g., height) that represent continuous variables with considerable overlap between sexes [35].
278 We used participants' self-reported sex as a proxy for karyotype sex. We applied this binary
279 classification as the basis to conduct an exploratory investigation of whether an individual's sex
280 was associated with pharmacodynamic responses to canagliflozin. In parallel, we compared
281 three approaches to normalizing our data – i.e., expressing drug-induced glucosuria relative to
282 body surface area, body weight, or urinary excretion of creatinine. When expressed as grams of
283 glucose per gram of creatinine, mean data were very similar in both males and females (Fig.
284 3B). In contrast, our data revealed substantial sex differences in mean quantities of
285 canagliflozin-induced glucosuria when expressed relative to body surface area (Fig. 3A) or body
286 weight (Fig. 3C). For example, canagliflozin induced an average of 37% more glucosuria in
287 males when expressed on the basis of grams of glucose per kg of body weight (Fig. 3C). These
288 data are consistent with weight loss data reported by the sponsors of dapagliflozin at the FDA's
289 Advisory Committee meeting on July 19, 2011 [36]. Specifically, 24 weeks of dapagliflozin therapy
290 induced greater placebo-subtracted weight loss in males than in females (2.76 kg versus 1.22
291 kg); the FDA's analysis concluded that the differential effect of sex was statistically significant
292 ($p=0.048$) – albeit there was considerable overlap between males and females with respect to
293 the magnitude of weight loss [36]. Also, many factors contribute to determining the magnitude of
294 weight loss in individual patients – including, for example, the magnitude of SGLT2 inhibitor-
295 induced compensatory increase in food intake [37]. Nevertheless, taken together, these data with
296 dapagliflozin are consistent with the hypothesis that the larger magnitude of SGLT2 inhibitor-

297 induced glucosuria in men (expressed per gram body weight) contributes to a larger magnitude
298 of mean drug-induced weight loss.

299 This case study exemplifies how routine study of sex as a biological variable does not
300 necessarily conflict with the aims of precision medicine as suggested by DiMarco et al. [35], but
301 rather enabled us to create an inclusive database containing data obtained in all participants –
302 regardless of their self-reported sex. Our experience demonstrates that investigations of sex as
303 a biological variable may offer opportunities for investigators to learn whether sex-related
304 variables emerge as being relevant in the context of their particular research programs.

305 This pilot study confirms the feasibility of conducting a pharmacogenomic study focused on
306 pharmacodynamic effects of canagliflozin in healthy volunteers. Based on assessment of
307 creatinine content of 24-hour urine collections, we conclude that participants in our study
308 provided complete collections of the urine produced during a 24-hour time period.
309 Reproducibility and completeness of urine collections are critical elements of a scientifically
310 rigorous clinical trial. We observed substantial inter-individual variation of our primary outcome
311 (i.e., canagliflozin-induced glucosuria) – varying over a twofold range from ~25 to ~50 grams of
312 glucose per gram of creatinine. By restricting our study to non-diabetic individuals with relatively
313 normal estimated glomerular filtration rates, we limited the contributions of two important
314 potential confounders. Inter-individual variation in fasting plasma glucose and creatinine
315 clearance accounted for ~1.4% and ~0.5% of the observed variance in canagliflozin-induced
316 glucosuria. Although our participants spanned a wide range of ages (35-82 years old), the
317 variation in age accounted for only ~5% of the variance in canagliflozin-induced glucosuria.
318 Finally, our studies of sex as a biological variable demonstrated that the magnitudes of
319 canagliflozin-induced glucosuria were similar in males and females when expressed on a per
320 gram-creatinine basis. Based on our observations, we conclude that >90% of the observed
321 variance in our primary endpoint is unexplained after accounting for contributions of age, sex,

322 renal function, and fasting plasma glucose. Accordingly, our ongoing pharmacogenomic study
323 (NCT02891954) is well positioned to define the contribution of genetic factors to the relatively
324 large residual variation in the pharmacodynamic effect of canagliflozin.

325

326

ACKNOWLEDGEMENTS

We gratefully acknowledge the National Institute of Diabetes and Digestive and Kidney Disease for the following research grants: R21DK105401, R01DK108942, T32DK098107, and P30DK072488. We also gratefully acknowledge contributions of the research participants and the skilled staff at the Amish Research Clinic for their critical roles in making this study possible. We are grateful to Mary Pavlovich, Melanie Daue, and Kathy Ryan for their help with database management. Dr. Laura Yerges-Armstrong provided genotype data enabling us to identify individuals to be invited to participate in this genotype-guided recruitment study.

337 **AUTHORS' CONTRIBUTIONS**

338 *Conception of the clinical trial and PI for NIH grant (R21DK105401)*: SIT

339 *Acquisition and analysis of data*: ALB, H-RC, MEM, EAS, SIT, HBW, ZSY

340 *Establishment of Old Order Amish genotypedatabase*: BDM, ARS

341 *Preparation of first draft of manuscript*: SIT

342 *Revising and approving final version of manuscript*: all authors

343 *Accountability for all aspects of work*: SIT

344

345

346 **Competing Interests**

347 SIT serves as a consultant for Ionis Pharmaceuticals and receives an inventor's share of
348 royalties from NIDDK for metreleptin as a treatment for generalized lipodystrophy. ARS is an
349 employee of Regeneron Genetics Center. BDM and MEM receive grant support from
350 Regeneron Genetics Center. BDM, MEM, EAS, and HBW have received partial salary support
351 from funds provided by RGC. ALB, ZSY, and HRC declare no competing interests.

352 **Table 1. Canagliflozin increases urinary sodium excretion (U_{Na}).**

353

Mean ± SEM (range)	Males	Females	Total
N (sample size)	13	17	30
Baseline U_{Na} (total mEq per 24 hrs)	252 ± 19	175 ± 11	208 ± 12
Post-cana U_{Na} (total mEq per 24 hrs)	293 ± 19[1] (p=0.13)	239 ± 29[1] (p=0.03)	263 ± 19[1] (p=0.007)
Δ U_{Na} (mEq per g-creatinine)	31 ± 14	55 ± 22	45 ± 14
Δ U_{Na} (mEq per m^2 body surface area)	19 ± 12	35 ± 15	28 ± 10
Δ U_{Na} (mEq per kg body weight)	0.46 ± 0.28	0.87 ± 0.36	0.68 ± 0.24

354

355 [1] **p-values calculated using Student's t-test for paired data in comparison to baseline**
356 **values for U_{Na}**

357 **FIGURES**

358 **Figure 1. Acute effects of canagliflozin on circulating biomarkers.** Baseline blood samples
359 were obtained for measurement of fasting plasma glucose (panel A), serum creatinine (panel
360 B), and serum uric acid (panel C). Canagliflozin (300 mg, p.o.) was administered 24 hours later
361 to each of the participants. Twenty-four hours after administration of canagliflozin, fasting blood
362 samples were obtained to assess the impact of canagliflozin on fasting plasma glucose, serum
363 creatinine, and serum uric acid. Data are presented as mean ± SEM (N=30).



364

365

366

367 **Figure 2. Correlations of glucosuria with urinary creatinine excretion and body surface**

368 **area.** Glucosuria (expressed as mg/day) is plotted as a function of either 24-hour urinary

369 creatinine excretion (mg/day) (panels A and C) or body surface area (m^2) (panels B and D).

370 Data are presented separately for males (panels A and B) and females (panels C and D). Using

371 data analysis programs provided in Excel, we estimated slopes for the least-square lines and

372 correlation coefficients. P-values were calculated using GraphPad Prism software.



373

374

375 **Figure 3. Sex differences with respect to the magnitude of canagliflozin-induced**

376 **glucosuria.** Using data presented in Figure 3, we calculated mean ± SEM for canagliflozin-

377 induced 24-hour urinary glucose excretion normalized in one of two ways: grams of glucose per

378 1.73 m^2 body surface area (Panel A) or grams of glucose per gram of creatinine (Panel B). Data

379 for male and female participants are represented as either black or gray columns, respectively.



380

381

382 **Figure 4. Canagliflozin-induced changes in serum uric acid and fractional excretion of**
383 **uric acid.** Panel A represents a plot of the effect of canagliflozin on serum uric acid level as a
384 function of the canagliflozin-induced increase in fractional excretion of uric acid. Both
385 parameters are presented as ratios of post-canagliflozin levels divided by pre-canagliflozin
386 levels. Panels B and C represents a plot of canagliflozin-induced fractional change in fractional
387 excretion of uric acid as a function of canagliflozin-induced glucosuria (grams of glucose per
388 gram of creatinine; panel B) or canagliflozin-induced natriuresis (expressed as a ratio of post-
389 canagliflozin values divided by pre-canagliflozin values; panel C). We estimated slopes for the
390 least-square lines and correlation coefficients using data analysis programs provided in Excel.
391 p-values were calculated using GraphPad Prism software.



392
393

394 **REFERENCES**

395 1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2
396 diabetes: a patient-centered approach: position statement of the American Diabetes
397 Association (ADA) and the European Association for the Study of Diabetes (EASD).
398 *Diabetes Care.* 2012;35(6):1364-1379.
399 2. Ali AM, Martinez R, Al-Jobori H, et al. Combination Therapy With Canagliflozin Plus
400 Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2
401 Diabetes. *Diabetes Care.* 2020;43(6):1234-1241.
402 3. Pawlyk AC, Giacomini KM, McKeon C, Shuldiner AR, Florez JC. Metformin
403 pharmacogenomics: current status and future directions. *Diabetes.* 2014;63(8):2590-2599.
404 4. Pearson ER. Dorothy Hodgkin Lecture 2021: Drugs, genes and diabetes. *Diabet Med.*
405 2021;38(12):e14726.
406 5. Rathmann W, Bongaerts B. Pharmacogenetics of novel glucose-lowering drugs.
407 *Diabetologia.* 2021;64(6):1201-1212.
408 6. Chedid V, Vijayvargiya P, Carlson P, et al. Allelic variant in the glucagon-like peptide 1
409 receptor gene associated with greater effect of liraglutide and exenatide on gastric
410 emptying: A pilot pharmacogenetics study. *Neurogastroenterol Motil.* 2018;30(7):e13313.
411 7. Mashayekhi M, Wilson JR, Jafarian-Kerman S, et al. Association of a glucagon-like peptide-
412 1 receptor gene variant with glucose response to a mixed meal. *Diabetes Obes Metab.*
413 2021;23(1):281-286.
414 8. Francke S, Mamidi RN, Solanki B, et al. In vitro metabolism of canagliflozin in human liver,
415 kidney, intestine microsomes, and recombinant uridine diphosphate
416 glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the
417 pharmacokinetics of canagliflozin in humans. *J Clin Pharmacol.* 2015;55(9):1061-1072.

418 9. Zhou K, Yee SW, Seiser EL, et al. Variation in the glucose transporter gene SLC2A2 is
419 associated with glycemic response to metformin. *Nat Genet.* 2016;48(9):1055-1059.
420 10. Beitelshees AL, Leslie BR, Taylor SI. Sodium-Glucose Cotransporter 2 Inhibitors: A Case
421 Study in Translational Research. *Diabetes.* 2019;68(6):1109-1120.
422 11. Taylor SI, Yazdi ZS, Beitelshees AL. Pharmacological treatment of hyperglycemia in type 2
423 diabetes. *J Clin Invest.* 2021;131(2).
424 12. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19
425 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. *JAMA.*
426 2009;302(8):849-857.
427 13. Collins FS, Tabak LA. Policy: NIH plans to enhance reproducibility. *Nature.*
428 2014;505(7485):612-613.
429 14. Rich-Edwards JW, Kaiser UB, Chen GL, Manson JE, Goldstein JM. Sex and Gender
430 Differences Research Design for Basic, Clinical, and Population Studies: Essentials for
431 Investigators. *Endocr Rev.* 2018;39(4):424-439.
432 15. Denny JC, Collins FS. Precision medicine in 2030-seven ways to transform healthcare. *Cell.*
433 2021;184(6):1415-1419.
434 16. Hsueh WC, Mitchell BD, Aburomia R, et al. Diabetes in the Old Order Amish:
435 characterization and heritability analysis of the Amish Family Diabetes Study. *Diabetes*
436 *Care.* 2000;23(5):595-601.
437 17. Agarwala R, Biesecker LG, Tomlin JF, Schaffer AA. Towards a complete North American
438 Anabaptist genealogy: A systematic approach to merging partially overlapping genealogy
439 resources. *Am J Med Genet.* 1999;86(2):156-161.
440 18. Agarwala R, Schaffer AA, Tomlin JF. Towards a complete North American Anabaptist
441 Genealogy II: analysis of inbreeding. *Hum Biol.* 2001;73(4):533-545.

442 19. Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through
443 alteration of uric acid transport activity in renal tubule by increased glycosuria. *Biopharm*
444 *Drug Dispos.* 2014;35(7):391-404.
445 20. Novikov A, Fu Y, Huang W, et al. SGLT2 inhibition and renal urate excretion: role of luminal
446 glucose, GLUT9, and URAT1. *Am J Physiol Renal Physiol.* 2019;316(1):F173-F185.
447 21. Suijk DLS, van Baar MJB, van Bommel EJM, et al. SGLT2 Inhibition and Uric Acid Excretion
448 in Patients with Type 2 Diabetes and Normal Kidney Function. *Clin J Am Soc Nephrol.*
449 2022;17(5):663-671.
450 22. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor,
451 induces dose-dependent glucosuria in healthy subjects. *Clin Pharmacol Ther.*
452 2009;85(5):520-526.
453 23. Sha S, Polidori D, Farrell K, et al. Pharmacodynamic differences between canagliflozin and
454 dapagliflozin: results of a randomized, double-blind, crossover study. *Diabetes Obes Metab.*
455 2015;17(2):188-197.
456 24. Busse D, Tang W, Scheerer M, et al. Comparison of pharmacokinetics and the exposure-
457 response relationship of dapagliflozin between adolescent/young adult and adult patients
458 with type 1 diabetes mellitus. *Br J Clin Pharmacol.* 2019;85(8):1820-1828.
459 25. Sokolov V, Yakovleva T, Chu L, et al. Differentiating the Sodium-Glucose Cotransporter 1
460 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative
461 Systems Pharmacology Modeling. *CPT Pharmacometrics Syst Pharmacol.* 2020;9(4):222-
462 229.
463 26. Blau JE, Bauman V, Conway EM, et al. Canagliflozin triggers the FGF23/1,25-
464 dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study. *JCI*
465 *Insight.* 2018;3(8).
466 27. Blau JE, Taylor SI. Adverse effects of SGLT2 inhibitors on bone health. *Nat Rev Nephrol.*
467 2018;14(8):473-474.

468 28. Iyengar MR, Coleman DW, Butler TM. Phosphocreatinine, a high-energy phosphate in
469 muscle, spontaneously forms phosphocreatine and creatinine under physiological
470 conditions. *J Biol Chem.* 1985;260(12):7562-7567.
471 29. Bianchi L, Diez-Sampedro A. A single amino acid change converts the sugar sensor SGLT3
472 into a sugar transporter. *PLoS One.* 2010;5(4):e10241.
473 30. Tazawa S, Yamato T, Fujikura H, et al. SLC5A9/SGLT4, a new Na+-dependent glucose
474 transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose.
475 *Life Sci.* 2005;76(9):1039-1050.
476 31. Witkowska K, Smith KM, Yao SY, et al. Human SLC2A9a and SLC2A9b isoforms mediate
477 electrogenic transport of urate with different characteristics in the presence of hexoses. *Am*
478 *J Physiol Renal Physiol.* 2012;303(4):F527-539.
479 32. Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studies. *Nature.*
480 2014;509(7500):282-283.
481 33. Legato MJ, Johnson PA, Manson JE. Consideration of Sex Differences in Medicine to
482 Improve Health Care and Patient Outcomes. *JAMA.* 2016;316(18):1865-1866.
483 34. Woitowich NC, Beery A, Woodruff T. A 10-year follow-up study of sex inclusion in the
484 biological sciences. *Elife.* 2020;9.
485 35. DiMarco M, Zhao H, Boulicault M, Richardson SS. Why "sex as a biological variable"
486 conflicts with precision medicine initiatives. *Cell Rep Med.* 2022;3(4):100550.
487 36. FDA. Advisory Committee Meeting for Dapagliflozin (July 19, 2011). 2011.
488 http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/En
489 docrinologicandMetabolicDrugsAdvisoryCommittee/UCM264312.pdf (downloaded, June 11,
490 2023)
491 37. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy Balance After
492 Sodium-Glucose Cotransporter 2 Inhibition. *Diabetes Care.* 2015;38(9):1730-1735.

493

Supplementary Appendix

Pharmacogenetics of SGLT2 Inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker

Simeon I. Taylor[1]*. Hua-Ren Cherng[2], Zhinous Shahidzadeh Yazdi[1], May E. Montasser[1], Hilary B. Whitlatch[1], Braxton D. Mitchell[1], Alan R. Shuldiner[1], Elizabeth A. Streeten[1], and Amber L. Beitelshees[1]

[1] Department of Medicine
Division of Endocrinology, Diabetes, and Nutrition
University of Maryland School of Medicine
Baltimore, MD 20201
USA

[2] Department of Radiation Oncology
University of Maryland School of Medicine
Baltimore, MD 20201
USA

* Correspondence: staylor2@som.umaryland.edu

Registration: NCT02462421 (clinicaltrials.gov)

Funding: Research grants from the National Institute of Diabetes and Digestive and Kidney Diseases: R21DK105401, R01DK108942, T32DK098107, and P30DK072488.

34 Table of Contents

35 1 | Inclusion/exclusion criteria p. 3

36 2 | Power calculations p. 4

37 3 | Conduct of clinical trial p. 5

38 4 | Clinical chemistry p. 6

39 5 | Disposition of research participants and adverse events (Fig. S1) p.7

40 Table S1. Demographics and baseline characteristics of study population p. 8

41 6 | Pilot pharmacogenomic investigation of genetic variants in three p. 9
42 candidate genes (*SLC2A9*, *SLC5A4*, and *SLC5A9*).

43 Table S2. Selected data stratified according to genotype p.12

44 Fig. S2. Effect of canagliflozin on urinary Na+ excretion p. 13

45 Fig. S3. Correlations among indices of body size (body weight, body surface area,
46 and daily creatinine production): impact of sex as a biological variable p. 14

47 Fig. S4. Correlations among indices of body size (body weight, body surface area,
48 and daily creatinine production): impact of sex as a biological variable p. 15

49 Fig. S5. Sex differences with respect to the magnitude of canagliflozin-induced
50 glucosuria when normalized relative to body weight p. 16

51 Fig. S6. Inter-individual variation in 24-hour urinary glucose excretion p. 17

52 Fig. S7. Correlation of estimated GFR (eGR) with measured creatinine clearance p. 18

53 Fig. S8. Correlation of urinary glucose:creatinine ratios in 24-hour urine collections
54 with selected parameters p. 19

55 7 | References p. 20

56

57

1 | Inclusion/exclusion criteria

To be eligible to participate in the clinical trial, individuals were required to be of Amish descent, at least 18 years old, and have BMI between 18-40 kg/m^2. We established the following exclusion criteria:

- Known allergy to canagliflozin
- History of diabetes, random glucose >200 mg/dL, or HbA1c $\geq$6.5%
- Taking any of the following medications: diuretics, antihypertensive medications, uric acid lowering medications, or other medications judged to interfere with interpretation of results obtained in the clinical trial.
- Diagnosis of significant chronic diseases affecting cardiovascular, gastrointestinal, pulmonary, or renal systems or other diseases judged to interfere with interpretation of results obtained in the clinical trial.
- Seizure disorder.
- Pregnancy (self-reported) or breast-feeding within the past three months.
- Estimated glomerular filtration rate < 60 mL/min/1.73 m^2
- Hematocrit <35%
- Liver function tests (ALT or AST) greater than two times the upper limit of normal
- TSH outside the normal reference range for the assay.
- Current symptoms of genitourinary infection or two or more genitourinary infections during the prior 12 months.
- History of osteoporosis-associated bone fracture
- History of unhealed foot ulcer

2 | Power calculations

We based our recruitment target of 110 individuals on power calculations to provide 80% power (α=0.05) to detect a 25% difference (~1.0 S.D.) in canagliflozin-induced glucosuria or a 55% (~0.85 S.D.) difference with respect to the magnitude of the canagliflozin-induced decrease in serum uric acid levels.

- 20 homozygotes for the nonsense mutation in *SLC5A4* (rs62239058; p.E139X)
- 20 homozygotes for the nonsense mutation in *SLC5A9* (rs850763; p.E593X)
- 25 homozygotes for the missense variant in *SLC2A9* (rs1689079; p.V253I)
- 45 “control” individuals who were homozygous for the major alleles of all three genes.

3 | Conduct of Clinical Trial

After potential participants signed informed consent forms, nurses (a) obtained a detailed medical history; (b) measured height, weight, and blood pressure; and (c) obtained blood samples for screening laboratory tests (hematocrit, fasting plasma glucose, serum creatinine, serum sodium, plasma TSH, and HbA1c). Eligible research subjects participated in two home visits:

- Visit #1. At the first study visit, the nurse explained the process. Women of reproductive age underwent home testing to exclude the possibility that they were pregnant. The research nurse obtained baseline blood samples and provided supplies needed for the study including a single canagliflozin tablet (300 mg) and supplies necessary for collection of two 24-hour urine samples. Research participants were instructed to take the canagliflozin tablet exactly 24 hours after initiating the first 24-hour urine collection. Participants initiated the second 24-hour urine collection immediately after completing the first and immediately after taking the canagliflozin tablet.

- Visit #2. The second home visit took place two days after the first visit and 24 hours after the participant had taken the canagliflozin tablet. The research nurse obtained blood samples to assess pharmacodynamic responses to canagliflozin and collected the two 24-hour urine collections. The nurses also obtained information to confirm whether the participant followed the instructions and to elicit information about possible adverse events.

4 | Clinical Chemistry

Blood samples were obtained by a research nurse at home visits and collected in test tubes as appropriate for each assay: EDTA anticoagulant (purple top tube) for measurement of hematocrit and HbA1c; heparin anticoagulant (green top tube) for measurement of TSH; gray top tubes containing sodium fluoride and potassium oxalate for measurement of fasting plasma glucose; red top tube for collecting serum samples. After placing gray, purple, and green top tubes on ice, blood samples were transported to the clinical laboratory at the Amish Research Clinic (maximum transport time, 2 hours). After centrifugation (3300 rpm for 10 min), plasma/serum was sent on the same day to Quest Diagnostics for assay. Participants were provided with “pee-splitter” containers, which were used for 24-hour urine collections. A boric acid tablet (1 gram; Sigma Aldrich, PN#B2625) was added to one bottle for collecting urine destined for glucose assays; urine collected in the other bottle was used for measurement of uric acid, sodium, and creatinine. Urine samples were placed on ice or in a refrigerator prior to being picked up by a research nurse for transport to the clinical laboratory at the Amish Research Clinic. Urinary creatinine, sodium, glucose, and uric acid were measured at Labcorp.

5 | Disposition and adverse events

Forty individuals were enrolled in this clinical trial between the dates of July 13, 2015 – April 13, 2016 (Fig. S1). Ten potential enrollees were excluded for the following reasons (Fig. S1): low hematocrit (1), low TSH levels (2), frequent genital infections (1), pregnancy (1), history of myocardial infarction (1), giant platelets (1), shortness of breath (1), diabetes (1), or antihypertensive medications (1). The remaining 30 participants completed the study. There were two adverse events of mild to moderate severity (Fig. S1). Prior to taking the study medication, one participant experienced an accident while driving a horse and buggy. Another participant experienced loose stools two days after having received a single dose of canagliflozin (300 mg). Both adverse events were judged as unlikely to have been related to participation in the clinical trial (Fig. S1).

Figure S1. CONSORT diagram: disposition and adverse events.



143 **Table S1. Demographics and baseline characteristics of study population.**

Mean ± SEM (range)	Males	Females	Total
N (sample size)	13	17	30
Age (years)	51.6 ± 3.3	62.5 ± 3.4	57.8 ± 2.5
BMI (kg/m^2)	26.5 ± 0.8	29.1 ± 1.4	28.0 ± 0.9
Fasting plasma glucose (mg/dL)	93.5 ± 2.5	92.0 ± 1.8	92.6 ± 1.5
HbA1c (%)	5.56 ± 0.08	5.81 ± 0.05	5.70 ± 0.05
Serum creatinine (mg/dL)	0.80 ± 0.03	0.68 ± 0.02	0.73 ± 0.02
Serum uric acid (mg/dL)	4.78 ± 0.28	4.06 ± 0.18	4.38 ± 0.17
eGFR (mL/min/1.73 m^2)	102 ± 4	92 ± 3	96 ± 3
Hematocrit (%)	44.4 ± 0.6	40.2 ± 0.7	42.0 ± 0.6

144

7| Pilot pharmacogenomic investigation of genetic variants in three candidate genes (*SLC2A9*, *SLC5A4*, and *SLC5A9*).

This pilot study was designed to investigate possible association of three candidate genetic variants with pharmacodynamic responses to an SGLT2 inhibitor: nonsense variants in *SLC5A4* (rs62239058; p.E139X) and *SLC5A9* (rs850763; p.E593X) and a missense variant in *SLC2A9* (rs1689079; p.V253I). *SLC5A4* and *SLC5A9* encode two homologs of SGLT2 (SGLT3 and SGLT4, respectively) [1,2]. *SLC2A9* encodes GLUT9, a transporter reported to exchange glucose for uric acid [3].

Renal tubular epithelial cells contain a sufficient number of glucose transporters to accomplish near-complete reabsorption of all the glucose molecules filtered in the glomerulus under normal physiological conditions. SGLT2 is located in the most proximal S1 segment of the proximal tubule and mediates reabsorption of ~90% of the filtered glucose load under normal physiological conditions [4]. SGLT1 is located downstream in the S3 segment of the proximal tubule and mediates reabsorption of the ~10% of the filtered glucose load that escapes SGLT2-mediated reabsorption under normal physiological conditions. In SGLT2 inhibitor-treated patients, SGLT1 has sufficient capacity to compensate partially for the impact of SGLT2 blockade. As a result, the usual doses of SGLT2 inhibitors induce urinary excretion of only 30-50% of the filtered glucose load [4,5], albeit there is substantial variation among individual patients with respect to the magnitude of urinary glucose excretion in response to SGLT2 inhibitors.

In designing this clinical trial, we considered the possibility that two other renal tubular transporters (in addition to SGLT1) might also contribute to reabsorbing glucose when SGLT2 is inhibited by a drug: SGLT4 and GLUT9. These two transporters were selected as candidates in our pilot study because of the existence of relatively common, functionally significant genetic variants in the genes encoding the two transporters: a nonsense mutation in *SLC5A9* (encoding

169 SGLT4) and a missense variant in *SLC2A9* (encoding GLUT9) [6,7]. SGLT4 is a homolog of
170 SGLT2 (encoded by *SLC5A2*) that cotransports sodium along with several hexoses including
171 fructose, mannose, glucose, or 1,5-anhydroglucitol [2]. Among other locations, SGLT4 is reported
172 to be expressed in the S1 and S2 segments of the proximal tubule [8]. We hypothesized that the
173 loss-of-function mutation in *SLC5A9* (rs850763**;** p.E593X; minor allele frequency = 0.15) might
174 promote canagliflozin-induced glucosuria by diminishing SGLT4-mediated glucose reabsorption.
175 GLUT9 (encoded by *SLC2A9*) is a member of the SLC2-family of glucose transporters that also
176 includes GLUT1, GLUT2, and GLUT4 among others. GLUT9 is reported to mediate exchange of
177 glucose for uric acid [3]. A missense variant (rs1689079; p.V253I; minor allele frequency = 0.16)
178 has been identified, which is associated with increased urinary excretion of uric acid and
179 decreased levels of uric acid in serum [6,7]. Some publications have proposed that GLUT9 may
180 mediate the uricosuric effect of SGLT2 inhibitors with the increased concentration of glucose in
181 renal tubular fluid driving counter-transport of uric acid [4,9,10]. We hypothesized that the p.V253I
182 variant might be associated with an alteration in canagliflozin-induced uricosuria and/or
183 canagliflozin-induced glucosuria.

184 *SLC5A4* encodes SGLT3, a homolog of SGLT2 that has lost the ability to transport glucose but
185 has retained the ability to transport sodium [11-13]. SGLT3 is expressed in the small intestine,
186 where it has been hypothesized to function as a glucose sensor by virtue of its activity as a
187 glucose-regulated sodium transporter [14,15]. Because SGLT3 has also been reported to be
188 expressed in kidney [15,16], we hypothesized that a loss of function mutation in *SLC5A4* might
189 enhance canagliflozin-induced natriuresis and/or diminish canagliflozin-induced glucosuria by
190 diminishing SGLT3-mediated sodium reabsorption. We did not observe any trends suggesting
191 that homozygosity for this nonsense mutation in *SLC5A4* (rs62239058; p. E139X; minor allele
192 frequency = 0.08) is associated with alterations in canagliflozin-induced glucosuria or uricosuria.
193 We did, however, observe a statistically insignificant trend (p=0.07) toward an increase in

194 canagliflozin-induced natriuresis – consistent with the presumed role of SGLT3 as contributing
195 to mechanisms of renal tubular reabsorption of Na^+ [1,13,16].

196 The clinical trial was terminated early when it became apparent that we would not meet our
197 recruitment targets within the available time and budget. Nevertheless, we analyzed data to
198 explore whether there might be preliminary trends suggesting possible association of
199 pharmacodynamic responses with any of the three genetic variants. Our primary outcome was
200 glucosuria – a pharmacodynamic biomarker for glycemic efficacy and weight loss. The four
201 genotype groups exhibited mean rates of urinary glucose excretion in the range from 36.9-39.1
202 g-glucose per g-creatinine (Table 3). None of the three genetic variants was associated with a
203 statistically significant difference when compared to the control group.

204 We confirmed previously published observations [6,7] that the p.V253I variant in SLC2A9
205 (rs1689079) was associated with decreased mean levels of serum uric acid levels (3.7 ± 0.27
206 versus 4.6 ± 0.20 mg/dL in the present study; p=0.02). A previous analysis in the Old Order
207 Amish [7] estimated an effect size of 0.44 ± 0.06 mg/dL per variant allele, which is similar to the
208 magnitude of the difference observed in the present study (0.9 mg/dL) for homozygotes carrying
209 two variant alleles. Thus, our current observations appear to have reproduced previously
210 published data. We did not, however, detect statistically significant association of any of the
211 genotypes with alterations in fractional excretion of uric acid – either at baseline or in response
212 to canagliflozin (Table S2). It is likely that our clinical trial lacked the statistical power to detect
213 genetic associations unless effect sizes were quite large.

214

215 **Table S2. Selected data stratified according to genotype.** Data are presented as means ±
216 SEM. p-values were calculated relative to the control group using t-tests for unpaired data
217 without correction of multiple comparisons.

Trait	Control	SLC2A9 (p.V253I; rs1689079)	SLC5A4 (p.E139X; rs62239058)	SLC5A9 (p.E593X; rs850763)
N	13	7	4	6
Male/Female	4M/9F	4M/3F	3M/1F	2M/4F
Glucosuria (g-glucose/ g-creatinine)	37.6 ± 2.1	36.9 ± 2.5 (p=0.86)	37.1 ± 3.3 (p=0.92)	39.1 ± 2.5 (p=0.63)
Serum uric acid (mg/dL)	4.6 ± 0.20	3.7 ± 0.27 (p=0.02)	5.25 ± 0.76 (p=0.47)	4.05 ± 0.23 (p=0.09)
Uric acid fractional excretion (pre-dose)	0.08 ± 0.0036	0.10 ± 0.011 (p= 0.17)	0.06 ± 0.019 (p=0.42)	0.09 ± 0.006 (p=0.09)
Uric acid fractional excretion (post-dose)	0.15 ± 0.0068	0.14 ± 0.0058 (p=0.39)	0.16 ± 0.021 (p=0.48)	0.15 ± 0.011 (p=0.99)
Canagliflozin-induced natriuresis (ratio of 24-hr urinary Na+ post-canagliflozin divided by pre-canagliflozin)	1.20 ± 0.12	1.66 ± 0.12 (p=0.07)	1.48 ± 0.41 (p=0.53)	1.18 ± 0.10 (p=0.92)

218
219

220 **Figure S2. Correlation of urinary Na+ excretion before and after administration of**
221 **canagliflozin.** *Panel A*. Individual participants' body weights are plotted as a function of
222 calculated body surface areas (r=0.99 for both males and females). *Panel B*. 24-hour
223 urinary creatinine excretion is plotted as a function of body surface area (r=0.68 for males
224 and r=0.65 for females). Data for males are represented by black circles and for females
225 with gray squares.



226

227

228 **Figure S3. Reproducibility of 24-hour urine collections.** After participants collected
229 the first 24-hour urine collection, they received one tablet of canagliflozin (300 mg, p.o.).
230 Immediately thereafter participants collected a second 24-hour urine collection. Data are
231 presented as mean ± SEM (N=30)



232 .

233

234 **Figure S4. Correlations among indices of body size (body weight, body surface**
235 **area, and daily creatinine production): impact of sex as a biological variable.**
236 *Panel A*: Individual participants' body weights (kg) are plotted as a function of body
237 surface area (sq. meters) with males indicated by blue circles and females by red
238 square symbols. Data are presented as mean ± SEM (N=30). *Panel B*: Individual
239 participants' 24-hour urinary creatinine excretion values are plotted as a function of
240 body surface area (sq. meters) with males indicated by black circles and females by
241 gray square symbols. Linear regression yielded equations of **Y**=939**X**-118 (males) and
242 **Y**=686**X**-250 (females) where **Y** represents 24-hour urinary creatinine (mg/day) and **X**
243 represents body surface area (sq. meters). For a body surface area of 1.8 m^2, the
244 equations predict 24-hour urinary creatinine excretion rates of 1572 mg/day (males) and
245 985 mg/day (females) – i.e., ~60% higher for males.

246



247

248 **Figure S5. Sex differences with respect to the magnitude of canagliflozin-induced**
249 **glucosuria when normalized relative to body weight.** Canagliflozin-induced
250 glucosuria (mg/kg/d) was plotted separately for males (black circles) and females (gray
251 squares) as a function of body weight (kg).



252
253

254 **Figure S6. Inter-individual variation in 24-hour urinary glucose excretion.** Using
255 data from Figs. 5 and 6, we constructed a histogram depicting the number of individuals
256 (y-axis) with various levels of 24-hour urinary glucose excretion (grams of glucose per
257 grams of creatinine). The observed data ranged between 26.5 to 48.5 g-glucose/g-
258 creatinine.



259

260

261 **Figure S7. Correlation of urinary glucose:creatinine ratios in 24-hour urine**
262 **collections with selected parameters.** Data from Figs. 5 and 6 were analyzed to
263 assess correlation of 24-hour urinary glucose excretion rates with fasting plasma
264 glucose (panel A), creatinine clearance rates (panel B), and age (panel C). We
265 estimated slopes for the least-square lines and correlation coefficients using data
266 analysis programs provided in Excel. P-values were calculated using GraphPad Prism
267 software.



268

269 **Figure S8. Correlation of estimated GFR (eGFR) with measured creatinine**
270 **clearance.** eGFR (calculated by Quest Diagnostics) is plotted on the y-axis as a
271 function of measured creatinine clearance. We calculated creatinine clearance based
272 on lab data obtained prior to administration of canagliflozin: serum creatinine and 24-
273 hour urinary creatinine excretion. *Left panel*, males; *right panel*, females.



274

References

1. Bianchi L, Diez-Sampedro A. A single amino acid change converts the sugar sensor SGLT3 into a sugar transporter. *PLoS One.* 2010;5(4):e10241.
2. Tazawa S, Yamato T, Fujikura H, et al. SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. *Life Sci.* 2005;76(9):1039-1050.
3. Witkowska K, Smith KM, Yao SY, et al. Human SLC2A9a and SLC2A9b isoforms mediate electrogenic transport of urate with different characteristics in the presence of hexoses. *Am J Physiol Renal Physiol.* 2012;303(4):F527-539.
4. Beitelshees AL, Leslie BR, Taylor SI. Sodium-Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research. *Diabetes.* 2019;68(6):1109-1120.
5. Wright EM. SGLT2 Inhibitors: Physiology and Pharmacology. *Kidney360.* 2021;2(12):2027-2037.
6. Li S, Sanna S, Maschio A, et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. *PLoS Genet.* 2007;3(11):e194.
7. McArdle PF, Parsa A, Chang YP, et al. Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in old order amish. *Arthritis Rheum.* 2008;58(9):2874-2881.
8. Lee JW, Chou CL, Knepper MA. Deep Sequencing in Microdissected Renal Tubules Identifies Nephron Segment-Specific Transcriptomes. *J Am Soc Nephrol.* 2015;26(11):2669-2677.
9. Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. *Biopharm Drug Dispos.* 2014;35(7):391-404.
10. Novikov A, Fu Y, Huang W, et al. SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1. *Am J Physiol Renal Physiol.* 2019;316(1):F173-F185.
11. You G, Lee WS, Barros EJ, et al. Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney. *J Biol Chem.* 1995;270(49):29365-29371.
12. Clancey CJ, Lever JE. Differential regulation of three glucose transporter genes in a renal epithelial cell line. *J Cell Physiol.* 2000;185(2):244-252.
13. Diez-Sampedro A, Hirayama BA, Osswald C, et al. A glucose sensor hiding in a family of transporters. *Proc Natl Acad Sci U S A.* 2003;100(20):11753-11758.
14. Freeman SL, Bohan D, Darcel N, Raybould HE. Luminal glucose sensing in the rat intestine has characteristics of a sodium-glucose cotransporter. *Am J Physiol Gastrointest Liver Physiol.* 2006;291(3):G439-445.
15. Sotak M, Marks J, Unwin RJ. Putative tissue location and function of the SLC5 family member SGLT3. *Exp Physiol.* 2017;102(1):5-13.
16. Kothinti RK, Blodgett AB, North PE, Roman RJ, Tabatabai NM. A novel SGLT is expressed in the human kidney. *Eur J Pharmacol.* 2012;690(1-3):77-83.